Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and thus can be usefully used in the treatment of lung cancer.

Abstract: In the case in which a lithium metal is used in order to increase the capacity of a lithium secondary battery, reversibility of charging and discharging is reduced due to dendrite, etc. A lithium metal having LiF deposited thereon exhibits high stability, whereby reversibility of charging and discharging is increased. In addition, in the case in which LiF is deposited, the lithium metal, which is a negative electrode material, is not consumed, and the shape of a lithium metal electrode is not greatly changed.

Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.

Abstract: A negative electrode including: a current collector; a first negative electrode active material layer positioned on at least one surface of the current collector for a negative electrode and containing a first carbonaceous active material; and a second negative electrode active material layer positioned on a surface of the first negative electrode active material layer and containing a silicon-based active material and carbon nanotubes. A lithium secondary battery including the negative electrode is also disclosed.

Abstract: A lithium metal is physically pressed to a silicon wafer having a uniform intaglio or embossed pattern formed thereon in advance, or liquid lithium is applied to the silicon wafer and may then be cooled in order to form a uniform pattern on the surface of the lithium metal.

Abstract: A haptic effect transmission method for providing real-time immersive content according to the present invention includes executing participatory content in which one or more users participate, collecting motion information of the users participating in the participatory content through a haptic device, multiplexing the motion information with video and audio files of the participatory content to obtain a multiplexed file, and demultiplexing the multiplexed file and providing the demultiplexed file to a display device and a haptic device of a client terminal.

Abstract: In the case in which a lithium metal is used in order to increase the capacity of a lithium secondary battery, reversibility of charging and discharging is reduced due to dendrite, etc. A lithium metal having LiF deposited thereon exhibits high stability, whereby reversibility of charging and discharging is increased. In addition, in the case in which LiF is deposited, the lithium metal, which is a negative electrode material, is not consumed, and the shape of a lithium metal electrode is not greatly changed.

Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.

Abstract: An apparatus and method, and a recording medium thereof, wherein the apparatus receives image data, recognizes, from the received image data, information selected from among image information and text information, controls one of the recognized image information and text information to be discriminately stored in a predetermined data format according to patient information, clinical information, and post-treatment change progress information, and displays, according to a request, a personal health record including the stored patient information, clinical information, and post-treatment change progress information.

Abstract: The disclosure includes a device and method for receiving image data, controlling to recognize one of image information and text information from the received image data and divide and store one of the recognized image information and text information into patient information and clinical information and change trend information according to treatment in a predetermined data format regardless of a language of the recognized text information, and displaying a personal health record including the stored patient information and clinical information according to a request and a recording medium thereof.

Abstract: The present invention relates to a biomarker composition for diagnosing radiation-resistant cancer comprising PMVK as an active ingredient and a method of diagnosing radiation-resistant cancer using the same, and when the PMVK is knocked down, it is confirmed that the survival rate of cancer cells decreases during radiation treatment, and based on this, the possibility as a factor related to radiation therapy resistance to cancer was suggested, and the PMVK can be used as a new target to enhance the effect of radiation therapy on human cancer cells.

Abstract: The present invention relates to a biomarker composition for diagnosing radiation-resistant cancer comprising PMVK as an active ingredient and a method of diagnosing radiation-resistant cancer using the same, and when the PMVK is knocked down, it is confirmed that the survival rate of cancer cells decreases during radiation treatment, and based on this, the possibility as a factor related to radiation therapy resistance to cancer was suggested, and the PMVK can be used as a new target to enhance the effect of radiation therapy on human cancer cells.

Abstract: Provided is a peptide for targeting gastric cancer, a composition for diagnosing radioresponsiveness-dependent gastric cancer using the peptide, and a drug delivery use of the peptide, wherein a functional peptide capable of targeting cancer has been discovered so as to implement personalized diagnosis and treatment for individual patients having cancer, consideration of problems occurring during treatment in which treatment cases of respective patients differ due to different therapeutic responses resulting from genetic differences in the individual patients.

Abstract: Provided is a peptide for targeting colorectal cancer, a composition for diagnosing radioresponsiveness-dependent prognosis of colorectal cancer using the peptide, and a drug delivery use of the peptide, wherein a functional peptide capable of targeting cancer has been discovered so as to implement personalized diagnosis and treatment for individual patients having cancer, in consideration of problems occurring during treatment in which treatment cases of respective patients differ due to different therapeutic responses resulting from genetic differences in the individual patients.

Abstract: The present invention relates to a biomarker composition for diagnosing radiation-resistant cancer comprising LRP-1 as an active ingredient and a method of diagnosing radiation-resistant cancer using the same, and identifies LRP-1 which a binding partner protein to which specific peptide sequences specifically targeting radiation-resistant colon cancer tissues are actually bound, and based on this, suggests the possibility of radiation therapy resistance factor for cancer.

Abstract: Provided is a peptide for targeting gastric cancer, a composition for diagnosing radioresponsiveness-dependent gastric cancer using the peptide, and a drug delivery use of the peptide, wherein a functional peptide capable of targeting cancer has been discovered so as to implement personalized diagnosis and treatment for individual patients having cancer, consideration of problems occurring during treatment in which treatment cases of respective patients differ due to different therapeutic responses resulting from genetic differences in the individual patients.

Abstract: The present disclosure relates to a biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof. The present disclosure provides a marker, a composition, and a kit for predicting the sensitivity to a protein kinase inhibitor, and a prediction method thereof. According to the present disclosure, the marker has an excellent effect of predicting the sensitivity to a protein kinase inhibitor, and thus the present disclosure can be useful for cancer treatment.

Abstract: The present invention relates to a method for isolating a nucleic acid from a sample comprising a formalin-fixed, paraffin-embedded (FFPE) tissue fragment, a kit for isolating the nucleic acid, and a lysis buffer for the same.

Abstract: Provided is a peptide for targeting colorectal cancer, a composition for diagnosing radioresponsiveness-dependent prognosis of colorectal cancer using the peptide, and a drug delivery use of the peptide, wherein a functional peptide capable of targeting cancer has been discovered so as to implement personalized diagnosis and treatment for individual patients having cancer, in consideration of problems occurring during treatment in which treatment cases of respective patients differ due to different therapeutic responses resulting from genetic differences in the individual patients.

Abstract: Provided is a peptide for targeting gastric cancer, a composition for diagnosing radioresponsiveness-dependent gastric cancer using the peptide, and a drug delivery use of the peptide, wherein a functional peptide capable of targeting cancer has been discovered so as to implement personalized diagnosis and treatment for individual patients having cancer, consideration of problems occurring during treatment in which treatment cases of respective patients differ due to different therapeutic responses resulting from genetic differences in the individual patients.